BMC is out with its report today on Optimer Pharmaceuticals OPTR, initiating OPTR at Buy.
In its report, BMC writes, "We are initiating coverage of Optimer Pharmaceuticals with a Buy Rating and a $20 target price. Our positive opinion is based primarily on the opportunity for the company's newly launched antibiotic, Dificid, to exceed sales expectations in the near and longer term."
Shares of OPTR closed Tuesday at $16.12, up 2.94% from Monday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in